Skip to content

Dr. Roberti Gloria

Ophthalmologist, Researcher
Roberti Gloria
Research line: Research Line of Glaucoma and anterior segment with ocular annexes
Research unit: RU Glaucoma
Simple Operating Unit: Simple Operating Unit Glaucoma and Hospital-Territory Integration 
Specialization: Ophthalmology
Professional register: Register of Physicians and Surgeons of Rome (Medical Board of the Province of Rome), No. 56456 dated 11 March 2008

Practices at IRCCS Fondazione G.B. Bietti at the premises of Via Livenza 3 and Via di Santo Stefano Rotondo 6, Presidio Ospedaliero Britannico, Rome.

Scientific Publications: PubMed

LinkedIn Profile: Gloria Roberti

  • 2001: Classical High School Diploma, Liceo Ginnasio Statale “Giulio Cesare,” Rome.
  • 2007: Degree in Medicine and Surgery (110/110 cum laude), University of Rome “Tor Vergata,” Rome.
  • 2012: Specialization in Ophthalmology (50/50 cum laude), University of Rome “Tor Vergata,” Rome.
  • 2011–2012: Glaucoma Research Fellowship, Moorfields Eye Hospital, London, UK.
  • 2011–2012: Part-time Glaucoma Clinical Fellow, Moorfields Eye Hospital, London, UK.
  • 2015: Second-Level Master’s Degree in Open-Angle Glaucoma: Epidemiology, Diagnostics, Therapy, Centro Unimol Management – University of Molise, Campobasso.
  • 2016: Advanced Training Course in Planning and Analysis of Observational and Experimental Clinical Studies, University of Rome “La Sapienza,” Rome.
  • 2017: PhD in Applied Medical and Surgical Sciences, University of Rome “Tor Vergata,” Rome.
  • 2012–2013: Research Fellow, Glaucoma Research Line, IRCCS Fondazione G.B. Bietti.
  • 2013–2019: Medical Researcher, Glaucoma Unit (UOS), IRCCS Fondazione G.B. Bietti.
  • 2020–present: Medical Researcher, Glaucoma Unit (UOS), IRCCS Fondazione G.B. Bietti.

  • Ordinary Member, Italian Association for the Study of Glaucoma (AISG)

  • Ordinary Member, Italian Society of Ophthalmology (SOI)

  • Clinical performance of COMPASS in glaucoma diagnosis: comparison with HFA.
  • Evaluation of efficacy, safety, and tolerability of Bimatoprost 0.01% (BIMMD) and Tafluprost single-dose 15 μg/mL (TUDPF, SAFLUTAN) in patients with glaucoma or ocular hypertension eligible for prostaglandin therapy: a six-month, multicenter, randomized, crossover, single-blind, investigator-masked European study (SPORT II).
  • Two-year multicenter, randomized, double-blind, parallel-group study on the safety of LUMIGAN® 0.1 mg/mL versus LUMIGAN® 0.3 mg/mL in patients with glaucoma or ocular hypertension.
  • Six-month, multicenter, randomized, double-blind, controlled study to evaluate the safety and efficacy of PG324 compared with Ganfort in patients with elevated intraocular pressure.
  • Preservative-free fixed combination of tafluprost 0.0015% / timolol 0.5% in patients with open-angle glaucoma or ocular hypertension: clinical efficacy, tolerability, and safety in clinical practice.
  • Safety and efficacy of brinzolamide 1% / brimonidine 0.2% (Simbrinza) twice daily as adjunctive therapy to travoprost 0.004% / timolol 0.5% (Duotrav).
  • Evaluation of the efficacy and safety of T4030 compared with single-dose Ganfort in patients with ocular hypertension or glaucoma.
  • Evaluation of spatial summation within the central 10 degrees of the visual field: development of a neural model for structure–function analysis.
  • Evaluation of β-amyloid concentration and intracellular proteolytic pathways in ocular tissues and fluids from patients undergoing combined glaucoma surgery with or without cataract surgery.
  • Evaluation of the IOP-lowering efficacy of the PreserFlo device, with or without cataract surgery, in glaucoma patients: a retrospective multicenter “before–after” study.
  • Evaluation of agreement among different perimetric grids in detecting central functional defects in glaucoma patients with thinning of ganglion cell layer measured by spectral-domain optical coherence tomography.
  • XEN GLAUCOMA TREATMENT REGISTER (XEN-GTR): Italian multicenter prospective observational study.
Skip to content